Contact information Verified work emails, personal emails, and direct dials — unlocked in one click.
Work email
•••••@geneombiotechnologies.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••
Free to start · No credit card required
Current company Geneombio Technologies
Biotechnology · 59 employees · Founded 2005 · Pune Maharashtra, India
geneOmbio Technologies Pvt. Ltd. ISO/IEC 17025:2017 & ISO 15189:2022 certified | Pune, India GeneOmbio is a precision-genomics company that turns molecular insight into measurable value for the life-science, pharma, and biopharma sectors. Why partners choose us • Comprehensive infrastructure Automated fluorescent DNA sequencers • high-throughput robotised real-time and multiplex-PCR platforms • NGS pipelines • PCR-qPCR workstations • gradient & conventional thermal cyclers • BSL-2 biosafety suites - all under GLP/GMP digital data control. • Molecular Diagnostic Services 60 single- & multiplex PCR assays validated for infectious diseases, congenital disorders, and pharmacogenetic markers, with Sanger and NGS confirmation options. • Pharma & Biopharma support Regulatory compliant cell-bank characterization, adventitious-agent screening, mycoplasma/endotoxin testing, and rapid microbial identification & strain typing to keep pipelines audit-ready. • Microbiome & Nutrigenomics Centre of Excellence Shotgun metagenomics • 16S/ITS amplicon sequencing • functional pathway analysis • personalised diet-gene panels—translating microbiome science into clinically actionable nutrition and probiotic solutions. • Contract Research & Bioinformatics Bespoke assay development, method validation, multi-omics data analytics and biostatistics from a PhD-level team of bioinformaticians and wet-lab scientists. • Proven delivery 300+ successful private and government projects, including flagship research grants, completed on time and in full regulatory geneOmbio combines rigorous quality systems with innovation to accelerate discovery, safeguard product quality, and advance precision medicine. Connect with us to move from gene to impact.